The latest price target for Centessa Pharmaceuticals (NASDAQ:CNTA) was reported by Guggenheim on November 15, 2024. The analyst firm set a price target for $28.00 expecting CNTA to rise to within 12 months (a possible 86.67% upside). 11 analyst firms have reported ratings in the last year.

The latest analyst rating for Centessa Pharmaceuticals (NASDAQ:CNTA) was provided by Guggenheim, and Centessa Pharmaceuticals maintained their buy rating.

The last upgrade for Centessa Pharmaceuticals PLC happened on September 19, 2024 when Morgan Stanley raised their price target to $26. Morgan Stanley previously had an equal-weight for Centessa Pharmaceuticals PLC.

The last downgrade for Centessa Pharmaceuticals PLC happened on August 12, 2022 when Morgan Stanley changed their price target from $10 to $5 for Centessa Pharmaceuticals PLC.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Centessa Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Centessa Pharmaceuticals was filed on November 15, 2024 so you should expect the next rating to be made available sometime around November 15, 2025.

While ratings are subjective and will change, the latest Centessa Pharmaceuticals (CNTA) rating was a maintained with a price target of $24.00 to $28.00. The current price Centessa Pharmaceuticals (CNTA) is trading at is $15.00, which is out of the analyst’s predicted range.